Ophthotech Corp (OPHT) Reports Update on Zimura Complement Programs for Treatment of Eye Diseases
Tweet Send to a Friend
Ophthotech Corporation (NASDAQ: OPHT) announced today the initiation of an open-label Phase 2a clinical trial of Zimura® (avacincaptad pegol), the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
